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Abstract
From its discovery as an adaptive bacterial and archaea immune system, the clustered regularly interspaced short
palindromic repeats (CRISPR)-Cas system has quickly been developed into a powerful and groundbreaking programmable
nuclease technology for the global and precise editing of the genome in cells. This system allows for comprehensive
unbiased functional studies and is already advancing the field by revealing genes that have previously unknown roles
in disease processes. In this review, we examine and compare recently developed CRISPR-Cas platforms for global
genome editing and examine the advancements these platforms have made in guide RNA design, guide RNA/Cas9
interaction, on-target specificity, and target sequence selection. We also explore some of the exciting therapeutic
potentials of the CRISPR-Cas technology as well as some of the innovative new uses of this technology beyond
genome editing.

Introduction
Clustered regularly interspaced short palindromic repeats
(CRISPR)-Cas systems are adaptive immune systems used
by many bacteria and archaea to fight off foreign DNA in
the form of bacterial phages and/or plasmids [1-5]. Although multiple CRISPR-Cas types (I, II, and III) and subtypes (I-A to I-F) have been identified in bacteria and
archaea, we pay particular attention to the specifics of the
type II since type II has been engineered and adapted for
use in eukaryotic systems, which is the focus of this review. Generally, the CRISPR-Cas system works through
RNA-directed endonuclease cleavage of the invading
genomic sequence. The invading sequence is captured
and inserted directly into the genome of the host organism between CRISPR regions (Figure 1A) [6-8]. Following foreign DNA infection, the sequences within the
CRISPR regions are transcribed as a single RNA transcript called a precursor CRISPR RNA (pre-crRNA). In
the CRISPR-Cas9 system, the pre-crRNAs are bound by
additional RNAs termed transactivating CRISPR RNAs
(tracrRNAs) [9-12]. Once bound, the pre-crRNAs are
processed into individual crRNA:tracrRNA duplexes by
RNase III and together form a complex with an endonuclease [9-12]. The endonuclease Cas9 that is encoded
* Correspondence: akasinski@purdue.edu
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West Lafayette, IN 47907, USA

from a region of the host genome adjacent to the
CRISPR region is directed to the invading DNA in a
sequence-dependent manner via the crRNA. Once
bound to the foreign DNA, Cas9 introduces a doublestranded break in the foreign DNA [11-13].
Realizing the potential power of a programmable nuclease to edit mammalian genomes, the CRISPR-Cas9 system
has since been commercially developed as a technology
for use in loss-of-function (LOF) studies [13,14]. Regardless of the platform, a tracrRNA, a mammalian optimized
Cas9 protein, and a small guide RNA (sgRNA) that is
analogous to the crRNA must be expressed at minimum.
In some engineered systems, the sgRNA and the
tracrRNA are expressed separately while in others, they
are expressed as a single transcript [14-16]. The sgRNA
sequences are generally 20-bp long, but sgRNA sequences
of 17–18 bp are also effective [17]. Target sequences must
be adjacent to a protospacer adjacent motif (PAM) sequence in the form of 5′-NGG (Figure 1B) [18-20]. Once
expressed in cells, the Cas9 protein, tracrRNA, and the
sgRNA form a complex, bind to the target sequence, and
make a double-stranded break in the target. The break is
repaired via the cellular process of nonhomologous end
joining (NHEJ), an error-prone process that introduces insertion, deletion, and frameshift mutations into the target
sequence. Targeted mutations can also be introduced by
cotransfecting single- or double-stranded oligodeoxynucleotides to promote homology-driven repair [21-28].
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Figure 1 The CRISPR-Cas9 bacterial immune system and design of a CRISPR-Cas9 target sequence. (A) The CRISPR-Cas system acts as an
adaptive immune system in bacteria and archaea. Clustered regularly interspaced short palindromic repeats (CRISPR) regions are stretches of repetitive
genomic bacterial or archaea DNA interspersed by segments of foreign DNA sequences captured from bacterial phages and plasmids. A cluster of Cas
(CRISPR associated) genes are located near the CRISPR region. The Cas9 gene, which is unique to type II CRISPR systems, codes for an RNA-guided
endonuclease. Following foreign DNA infection in type II CRISPR systems, the CRISPR region is transcribed as a single RNA transcript called a pre-crRNA,
and in type II systems, the pre-crRNAs are bound by tracrRNAs, processed into individual crRNA:tracrRNA duplexes by RNase III and form a complex
with Cas9. The crRNA sequences are complementary to the foreign DNA and direct the Cas9 nuclease to form a complex with the foreign DNA and
introduce a double-stranded break. (B) CRISPR-Cas9 target sequences are 20-nt long and are flanked by a protospacer adjacent motif (PAM) sequence
in the form of 5′-NGG.

In studying the molecular signaling pathways that impinge on disease processes, many large- and small-scale
expression studies of diseased tissues have provided extensive lists of genes that are aberrantly expressed in diseases such as cancer [29]. Such studies have greatly
advanced our knowledge about the gene expression signatures of disease and provided us with a wealth of
genes that are important predictive and prognostic biomarkers. The challenge moving forward is how to effectively separate the genes that are ‘drivers’ of disease from
gene ‘passengers’ whose aberrant expression has no relevance to the disease state. Loss-of-function studies are
an effective way to assess whether a gene is a driver of
disease or a passenger.
The CRISPR-Cas system has some important advantages
over other methods in LOF studies. At present, a widely
used method for knocking down the expression of genes is
through the induction of RNA interference (RNAi) either
through transfection or viral transduction of small interfering RNAs (siRNA) or short hairpin RNAs (shRNA)
[30-34]. While the use of RNAi has certainly advanced
many fields, there are also some inherent drawbacks. First,
siRNAs and shRNAs must be continuously expressed

for longitudinal studies, which can lead to confounding
off-target effects and false negatives [35]. Second, knockdown by these methods can often be incomplete [36,37].
Gene knockout technologies, such as those mediated by
CRISPR-Cas9, overcome such deficits by knocking out individual gene expression at the genomic level and do so
with minimal off-target effects. And while RNAi is limited
to inhibiting the function of RNAs, CRISPR-Cas9 technology can be used to introduce random or targeted mutations into any portion of the genome such as the coding
region, promoter, or enhancer regions of genes [38].
Importantly, the CRISPR-Cas9 system has recently
been developed into a tool for genome-scale loss-offunction screens by several laboratories. In this review,
we examine and compare these recently developed
genome-scale technologies. We also explore some of the
potential therapeutic and innovative new uses of the
CRISPR-Cas technology beyond genome editing.
Genome-scale CRISPR-Cas9 platforms (single Cas systems)

The various genome-scale CRISPR-Cas9 platforms target
genes by directing either a single Cas9 protein to each
targeted gene (referred to here as a single Cas system) or
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by directing two Cas9 proteins to each targeted gene (referred to here as a dual Cas system). Shalem and colleagues recently developed a single Cas lentiviral
genome-scale CRISPR-Cas9 KnockOut (GeCKO) library
[39]. Each lentiviral vector in the library delivers stable
expression of Cas9, a specific sgRNA generated against a
single gene, and a puromycin selection marker to the
cell. In total, 64,751 unique lentiviral vectors make up
the GeCKO library that target 18,080 human genes. This
powerful new method of interrogating gene function on
a genome-wide scale was used in both positive and negative selection screens in human cells. First, to test the
ability of the GeCKO library to identify genes critical to
survival, a negative selection screen was conducted by
transducing a human melanoma cell line and a human
stem cell line with the GeCKO library. Comparing the
deep sequenced population of sgRNAs present in the initially transduced cells to the deep sequenced population
of sgRNAs present in cells that survived 14 days post
transduction revealed a reduction in sgRNA diversity due
to the depletion of sgRNAs targeting genes critical for survival. Importantly, this type of negative selection screen
not only allows for the identification of gene sets that are
critical to the survival of both cancer and noncancer cells
but also identifies gene sets that are unique to the survival
of cancer cells and thus genes that are possible therapeutic
targets. GeCKO was also effective in a positive selection
screen that enriched for sgRNAs that knock out genes essential for chemotherapeutic response. A375 melanoma
cells, which are sensitive to the B-RAF serine/threonine
protein kinase inhibitor vemurafenib, were transduced
with the GeCKO library and grown in the presence of
vemurafenib. After 14 days, a group of cells had been rendered drug resistant. Deep sequencing of the population
of sgRNAs present in the drug-resistant cells versus the
vehicle-treated cells revealed the enrichment of multiple
sgRNAs directed against a subset of genes, suggesting that
loss of those particular genes likely contribute to vemurafenib resistance. Importantly, this type of unbiased loss-offunction assay identified several genes not previously implicated in vemurafenib resistance, which opens up completely new avenues of research into the mechanisms of
vemurafenib resistance. Recently, vast improvements have
been made to the GeCKO library platform [40]. First, a
newly modified vector, lentiCRISPRv2, was generated that
displays a tenfold increase in viral titer over the original
lentiCRISPRv1 vector. The modified vector, lacking one of
two nuclear localization signals contained in the lentiCRISPRv1 vector, has been human-codon optimized, and
the U6-driven sgRNA cassette has been repositioned. Secondly, to increase viral titer even further, a two-vector system was generated in which Cas9 and sgRNAs are
expressed from separate viral vectors (lentiCas9-Blast and
lentiGuide-Puro) with distinct antibiotic selection markers.
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LentiGuide-Puro has a 100-fold increase in viral titer over
the original lentiCRISPRv1 vector. Also, the number of human genes targeted by the sgRNA library was increased to
19,050, guide RNAs targeting 1,864 miRNAs were included, and a sgRNA library against 20,611 mouse proteincoding genes and 1,175 miRNAs was also generated.
Importantly, these powerful new reagents are available to
the academic community through Addgene.
A similar large-scale study also utilized the CRISPRCas9 system to develop a lentiviral library containing
73,000 sgRNAs against 7,114 genes that was used for
genetic screens in human cells [41]. The library was
transduced into cells stably expressing Cas9. This library
proved effective in positive and negative selection
screens at identifying genes important to the mismatch
repair pathway and genes required for cellular proliferation. Critical parameters for designing effective sgRNAs
were also identified in this study. Careful dissection and
evaluation of the sgRNAs revealed that guide sequences
with very high or low GC content were less effective
against their targets, sgRNAs targeting the last coding
exon were less effective than those targeting earlier
exons, and sgRNAs targeting the sense strand were less
effective than those targeting the antisense strand. The
authors further hypothesized that differences in sgRNA
efficacy might also result from sequence features governing the interaction between the sgRNA and Cas9. To
test this, a method to profile the sgRNAs directly bound
to Cas9 in a highly parallel manner was developed. By
comparing the abundance of sgRNAs bound to Cas9
relative to the abundance of corresponding genomic
integrants, it was found that the nucleotide composition
near the 3′ end of the spacer sequence was the most important determinant of Cas9 loading. Cas9 preferentially
bound sgRNAs containing purines in the last four nucleotides of the spacer sequence over sgRNAs containing
pyrimidines in the same location. Using this algorithm, a
whole-genome sgRNA library was developed with great
promise for use in future genome-scale screening.
An additional genome-wide lentiviral CRISPR-sgRNA
library was generated containing 87,897 sgRNA targeting
19,150 mouse genes for comprehensive loss-of-function
screening in mice [42]. A lentiviral vector was used to
express the sgRNAs in embryonic stem cells stably expressing Cas9. A functional screen using this platform
revealed 27 known and 4 previously unknown genes that
modulate toxin susceptibility demonstrating the power
and utility of CRISPR-Cas-based genome-wide loss-offunction screening.
One concern of the single Cas systems is the potential
of off-target mutations introduced by the binding of
CRISPR-Cas9 to target sequences that may appear more
than once in the genome or to sites similar enough to the
target sequence that allow binding of the sgRNA [43-45].
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To examine the degree of off-targeting in the GeCKO library, developed by Shalem and colleagues [39], on- and
off-target allele modification frequencies were measured
by deep sequencing the targeted region at 3–5 predicted
potential off-target genomic regions for each of 12 different sgRNAs. Near 100% allele modification in the targeted
regions for all 12 sgRNAs was verified with only 3 sgRNAs
showing appreciable modification to one or more of the
predicted off-target regions (Table 1). Wang and colleagues also analyzed off-target activity in their lentiviral
CRISPR-Cas library [41]. Cas9 and a guide RNA directed
at the adeno-associated virus integration site 1 (AAVS1)
locus were stably expressed in a near-haploid human
chronic myelogenous leukemic cell line cells for 2 weeks.
The sgRNA target region along with 13 predicted potential off-target sites were examined by high-throughput sequencing. Cleavage of the target region occurred 97% of
the time with off-target sites mutated 0–2.5% (Table 1).
The authors note that the one off-target site with appreciable cleavage had perfect complementarity to the terminal 8 bp of the sgRNA and that on average, all sgRNAs
are predicted to have 2.2 such sites in the genome that almost always occur in noncoding areas of the genome. An
additional study tested two sgRNAs for each of 26 genes
[42]. Deep sequencing revealed that 50 of the 52 sgRNAs
analyzed were able to induce double-stranded breaks in
the target genes with variable cutting frequencies (Table 1)
with relatively low off-targeting (Table 1).
Genome-scale CRISPR-Cas9 platforms (dual Cas systems)

The low but still measurable frequency of off-target mutations in the single Cas systems discussed above has
been improved to essentially undetectable levels by the
development of dual cas platforms (Table 1). To increase
the specificity of RNA-guided nucleases, the
dimerization-dependent Fok1 nuclease domain was
fused to a catalytically inactive Cas9 (dCas9) protein
[46]. In this system, sequence-specific DNA cleavage
only occurs upon dimerization of two Fok1 nuclease
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domains from two different RNA-guided Fok1 nucleases
(RFNs) that are bound in close proximity to two unique
target sites (called half-sites) (Figure 2A, B). To be fully
effective, the half-sites must be 14–17 bp apart and the
entire target sequence must be flanked on the 5′ end by
the sequence 5′-CCN and flanked on the 3′ end by the
sequence NGG-3′. This system requires the use of two
sgRNAs (one for each half-site). As the authors note, a
full 44 bp RFN target site would almost always be
unique in the genome unless located in a duplicated area
of the genome. However, to assess the potential of offtargeting by RFNs, all sites in the genome that most
closely matched the target regions of 3 RFNs were identified. Deep sequencing analysis of these areas following
RFN-directed target mutagenesis detected no mutations
above background (Table 1). This data suggests that
RFN technology offers extraordinary precision. Ontarget mutation frequencies induced by RFNs at 12 different target sites in 9 different human genes ranged between 3 and 40% (Table 1). Some important cost
advantages to this platform are that the plasmids to express the Cas9/Fok1 fusion proteins and the sgRNAs are
inexpensive to purchase and the software to locate suitable target sequences against a gene of interest is publicly available. However, if one is generating an extensive
library of RFNs against hundreds or thousands of genes,
then the additional costs of generating two sgRNAs per
target for the RFN technology may be a concern [46].
A separate dimeric CRISPR RNA-guided Fok1 nuclease architecture was also recently developed [47]. Four
configurations of the Fok1 nuclease, dCas9, and nuclear
localization signal (NLS) were generated and tested for
DNA cleavage. Of the four, only the NLS-Fok1-dCAS9
architecture generated a high frequency of cleavage. And
although the NLS-Fok1-dCas9 (fCas9) system was
shown to modify target sequences with lower efficiency
than wild-type Cas9, the ratio of on-targeting/off-targeting was higher than that of wild-type Cas9 and paired
Cas9 nickases proving it to be a technology with a very

Table 1 Summary of reported on- and off-target mutation frequencies of single and dual CRISPR-Cas9 systems
Investigators

Platform

Reported on-targeting (%)

Reported off-targeting (%)

Shalem et al., 2014 [39]

Single Cas platform

~100

0–15b

Wang et al., 2014 [41]

Single Cas platform

97

0–29.5c

Koike-Yusa et al., 2014 [42]

Single Cas platform

12.7

~0.7d

Tsai et al., 2014 [46]

Dual Cas platform

3–40

0

Ran et al., 2013 [48]

Dual Cas platform

40a

0

Guilinger et al., 2014 [47]

Dual Cas platform

8–22

0

On-target mutation frequencies of up to 40% were observed in target sequences when the distance between the Cas9 nickase pairs were between −4
and +20 bp.
b
9 of 12 sgRNAs showed minimal (~0–3%) modification of predicted off-target sites. 3 of 12 sgRNAs showed modification (~15% or higher) on at least 1 of their
off-target sites.
c
0–2.5% cleavage of 12 of the 13 predicted off-target sites, 29.5% cleavage of 1 of the 13 predicted off-target sites.
d
Cleavage analysis of 275 potential off-target sites for the Pigga site 2 sgRNA revealed only 2 of those potential off-target sites were cleaved and both were in
noncoding regions (2/275*100 = ~0.7%).
a
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Figure 2 Dual CRISPR-Cas technologies that increase nuclease specificity. (A, B) Dimeric CRISPR RNA-guided Fok1 nuclease target sequences
consist of two 20 nt half-sites flanked by a protospacer adjacent motif (PAM) sequence in the form of 5′-NGG that are separated by a 14–17 nt spacer
sequence. Each half-site is bound by a Cas-9/Fok1 fusion protein. Once bound, the Fok1 domains of two different Cas-9/Fok1 fusion proteins dimerize
and introduce a double-stranded break in the spacer sequence. (C) Dual RNA-guided CRISPR-Cas9 nickase system. In this system, two sgRNAs are expressed
that each guide a mutant version of Cas9 (Cas9-D10A) (that only nicks one strand of the DNA rather than making a double-stranded cut) to two different
sequences that flank the target region. The two Cas9 nickases bind to opposite strands of the DNA nicking both DNA strands flanking the target region.
This introduces a site-specific double-stranded break that is then repaired by NHEJ.

high degree of specificity (Table 1). fCas9 was shown to
effectively cleave target sites in which the sgRNA binding sites were spaced 15–25 bp apart giving a more flexible range than the 14–17 bp spacing requirement of the
RFNs. Though this system has not yet been developed
into a genome-scale editing system, the authors report
that target sites conforming to the substrate requirements of fCas9 occur on average every 34 bp suggesting
it has the versatility to be developed into a genome-wide
editing approach.
Another strategy employed to address the issue of
CRISPR-Cas9 specificity makes use of a mutant version
of Cas9 (Cas9-D10A) that only nicks one strand of the
DNA rather than making a double-stranded cut [48]. In
this system, two sgRNAs are expressed that each guides
a Cas9-D10A nickase to two different sequences that
flank the target region (Figure 2C). The two Cas9
nickases bind to opposite strands of the DNA. Nicking
of both DNA strands introduces a site-specific doublestranded break that is then repaired by NHEJ. Similar to
the RFN technology, the use of two sgRNAs instead of
one to introduce a double-stranded break has the potential to greatly increase specificity. However, a potential
caveat of this system is that nicks introduced by the
binding of a single Cas9-D10A/sgRNA complex to an
off-target region could lead to off-target mutations

[17,18,48,49]. To address this issue, the off-target mutation rates of Cas9-D10A transfected with one or two of
its sgRNAs were measured and compared with the offtarget mutation rate of wild-type Cas9 (WT-Cas9) at five
potential off-target sequences. Deep sequencing revealed
off-targeting (~3–35%) at all potential sites by WT-Cas9.
However, off-targeting by Cas9-D10A transfected with one
or two of its sgRNAs was not detected above background
(Table 1). A second experiment measuring off-targeting for
two different guide RNAs gave similar results. On-target
mutation frequencies of up to 40% were observed in target
sequences when the distance between the Cas9 nickase
pairs were between −4 and 20 bp (Table 1).
In addition to the development of dual Cas9 platforms,
other advances have been made to improve the specificity of CRISPR-Cas technology. It has recently been
demonstrated that truncated sgRNAs (tru-gRNAs),
which are deleted at the 5′ end resulting in a shorter
17–18 nucleotides sgRNA, are more sensitivity to mismatched bases. Thus, they display reduced off-target
mutation rates while maintaining the efficiency of ontarget modifications [17]. Conversely, the addition of
two guanines at the 5′ end of sgRNAs greatly decreased
off-target mutation rates; however, the GGX20 sgRNAs
were less active at on-target sites [50]. An additional
mechanism to decrease off-targeting is to reduce the
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amount of Cas9 and sgRNA DNA delivered to cells;
however, this approach leads to a reduction in on-target
cleavage [43,44].
A summary of the previously discussed genome-scale
single and dual Cas systems can be found in (Table 1).
All are excellent technologies with exciting implications
for ongoing research. A clear trade-off for the impressively low off-target mutations rates of the dual Cas9
systems appears to be their lower on-target mutation
rates relative to the single Cas9 systems. Depending on
the needs of the investigator, the larger, but still small,
degree of off-targeting by the single Cas9 systems may
be an acceptable trade-off for their relatively higher ontarget mutation rates. In addition to the global editing
platforms discussed here, there are a plethora of other
exciting CRISPR-Cas platforms for editing the genome
on a smaller scale that have been developed and are
evolving [9,50,51].
CRISPR-Cas therapeutic potential

The ability to engineer genomic DNA in cells and organisms
will lead not only to major advances in the investigation of
disease processes but will also drive therapeutic innovations
[52]. An exciting potential use of the CRISPR-Cas system is
to correct disease-causing genetic mutations. For example,
CRISPR-Cas9 genome editing has been used to correct mutations in a human cell line that causes cystic fibrosis and in
murine zygotes that causes cataracts [25,26]. More recently,
a rare, but fatal, genetic condition caused by a mutation of
the fumarylacetoacetate hydrolase (FAH) gene in liver cells
was corrected using CRISPR-Cas9 [27]. Components of the
CRISPR-Cas9 system along with a homology-driven repair
template were delivered to liver cells by hydrodynamic injection. The injection resulted in a subpopulation of liver
cells (1/250) in which the wild-type sequence of the Fah
gene had been knocked in replacing the mutated sequence.
The repaired liver cells displayed expression of the wildtype Fah protein, exhibited a growth advantage over uncorrected cells, and expanded, resulting in a rescue of the body
weight loss phenotype displayed by mutant mice.
CRISPR-Cas9-mediated genome editing was also used
to correct a genetic mutation in mdx mice, the mouse
model of Duchenne muscular dystrophy (DMD) [28].
Mdx mice (C57BL/10ScSn-Dmdmdx/J) contain a nonsense mutation in exon 23 of the mouse dystrophin gene
introducing a premature stop codon, which leads to the
absence of full-length dystrophin and a human DMD-like
phenotype [53]. CRISPR-Cas9 plus a sgRNA targeting
exon 23 of the dystrophin gene and a single-stranded oligodeoxynucleotide used as a template for HDR-mediated
gene repair were injected into the pronucleus of mdx
mouse zygotes. The injected zygotes were then implanted
into pseudo-pregnant females and once born were monitored for defects in muscle structure and function. The
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pups were mosaic for the genetic correction (2 to 100%)
likely reflecting that in some zygotes, the genetic correction occurred at some point after the one-cell stage. Interestingly, the degree of phenotypic rescue exceeded the
degree of mosaicism. The authors point out that this likely
reflects an advantage of the corrected cells and their contribution to regenerating muscle.
CRISPR-Cas9 technology has likewise shown promise as
a therapeutic against viral infection. The clearance of
intrahepatic hepatitis B viral (HBV) templates in vivo has
been achieved using the CRISPR-Cas9 system [54]. This
indicates the potential of CRISPR-Cas9 to be used as a
therapeutic to eradicate persistent HBV infection in patients. Additionally, the CRISPR-Cas9 system was utilized
to target specific sequences within the human immunodeficiency virus (HIV)-1 long terminal repeats promoter
U3 region [55]. The targeted regions of the HIV genome
were edited following introduction of Cas9/sgRNA expression. In microglial, promonocytic, and T lymphocytes latently infected with HIV, the CRISPR-Cas editing inactivated
viral gene expression and replication. Importantly, off-target
mutations were not detected in the host cells expressing
Cas9/sgRNA and no genotoxicity was observed. A 9-kb
fragment of integrated proviral DNA was completely excised from the host cell genome by Cas9/sgRNA editing.
Additionally, continued expression of Cas9/sgRNA in host
cells prevented HIV-1 infection of those cells. The authors
note that this data suggests that Cas9/sgRNA can be engineered to provide a specific, effective, prophylactic, and
therapeutic approach against HIV/AIDS.
Potential therapeutic advances in the field of oncology
are also on the horizon. Chimeric antigen receptor
(CAR) T cell therapy is a personalized cancer immunotherapy [56]. In CAR T therapy, a patient’s own T cells
are collected, genetically engineered to produce receptors that recognize a specific protein (antigen) on tumor
cells [57]. The T cells are then infused back into the patient where they use their engineered receptors to target
and kill cancer cells that express the antigen on the surface of their membranes [56,57]. Novartis has recently
gained rights to use Intellia’s CRISPR gene-editing technology to engineer chimeric antigen receptor T cells (CAR-Ts)
for the purpose of developing CRISPR-Cas-based CAR
therapies [58]. Novartis has also partnered with Caribou
Biosciences “to research new CRISPR-based drug target
screening and validation technologies” [58].
More than just a nuclease

Using the CRISPR-Cas system for genome editing is just
the beginning of its utility. For example, CRISPR-Cas can
be used to regulate the expression of genes. Catalytically
inactive Cas9 (dCas9) guided to the promoter region of a
gene can repress transcription by interfering with transcriptional elongation (Figure 3A) [59,60]. Transcriptional
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Figure 3 Applications for the CRISPR-Cas9 system beyond gene editing. (A) CRISPR-Cas9 as a tool for inhibiting transcriptional activation.
sgRNAs can be used to direct the binding of catalytically inactive Cas9 (dCas9) to the promoter regions of genes. Once bound, dCas9 can interfere with
transcriptional initiation of the gene and thus inhibit gene expression. (B) CRISPR-Cas9 to promote the transcription of a gene. sgRNAs can be used to
direct the binding of a catalytically inactive Cas9 protein fused to a transcriptional activation domain (dCas9/TAD) to the promoter regions of genes.
Once bound, dCas9/TAD can promote transcription of the target gene. (C) CRISPR-Cas9 to image various elements of the genome. sgRNAs can be
used to direct the binding of catalytically inactive Cas9 fused to enhanced green fluorescent protein (dCas9/EGFP) to various elements of the genome.
This technology can be used to image different elements of a chromosome, telomeres in this example, in live cells. Dynamic chromosomal changes
during growth and replication can also be imaged.

repression can be enhanced by fusing a transcriptional repression domain to dCas9 [61,62]. Likewise, dCas9 can be
fused to a transactivation domain and be used to upregulate the expression of a gene (Figure 3B) [49,63-66].
Imaging of various elements in the genome of live cells
can also be accomplished using the CRISPR-Cas9 system.
An enhanced green fluorescent (EGFP)-tagged catalytically inactive Cas9 (dCas9) proteins can be guided to genomic elements via sequence-specific sgRNAs (Figure 3C)
[67,68]. The dCas9-EGFP and modified sgRNAs designed
to have increased stability and enhanced Cas9 binding
were used to image telomere dynamics in living cells during elongation and disruption and cohesion of replicated
loci on sister chromatids and their behaviors during mitosis. This technology allows for the visualization of chromatin dynamics in living cells with results that are on par
with fluorescent in situ hybridization. The dCas9-EGFP
imaging system has the potential to improve the capacity
for studying the conformation and dynamics of native
chromosomes in living cells. Beyond what has been
highlighted here, there are many other applications of
CRISPR-Cas beyond genome editing. The reader is referred to the following references that cover additional applications [50,51].

Conclusions and implications for functional
studies
The number of recent innovations to the CRISPR-Cas system has been enormous. CRISPR-Cas platforms continue

to evolve with constantly improving sgRNA design, ontarget specificity, and target sequence selection algorithms. With respect to cancer and other disease-related
research, there is an urgent need for unbiased comprehensive functional studies of genes in disease. CRISPR-Cas9 is
a scalable and effective new technology that can be used
to knock out individual gene expression in large scale at
the gene level and do so with minimal off-target effects.
These types of large-scale unbiased loss-of-function studies will help to both separate genes that are drivers of disease from passengers and will create entirely new avenues
for therapeutic investigation. Further, though many hurdles remain, CRISPR-Cas is beginning to show therapeutic
potential for use in the correction of disease-causing genetic mutations. Finally, novel innovations in CRISPR-Cas
technology beyond gene editing are expanding its utility
as a tool for modulating gene expression and imaging
chromatin dynamics in living cells. The continued
innovation of programmable nuclease technologies such
as CRISPR-Cas9 and their contributions to disease research and therapeutics will remain an exciting area of research to follow for the foreseeable future.
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